erythrosine and bortezomib

erythrosine has been researched along with bortezomib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chiang, AK; Hui, KF1
Boháčová, V; Breier, A; Kyca, T; Mišák, A; Pavlíková, L; Poturnayová, A; Šereš, M; Sulová, Z1

Other Studies

2 other study(ies) available for erythrosine and bortezomib

ArticleYear
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
    International journal of cancer, 2014, Dec-15, Volume: 135, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Proliferation; Depsipeptides; DNA Damage; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Fluoresceins; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species

2014
Insight into Bortezomib Focusing on Its Efficacy against P-gp-Positive MDR Leukemia Cells.
    International journal of molecular sciences, 2021, May-23, Volume: 22, Issue:11

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Deubiquitinating Enzymes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoresceins; Gene Expression Regulation, Neoplastic; Genes, cdc; Humans; Inhibitory Concentration 50; Leukemia, Lymphoid; Mice; Neoplasm Proteins; Protease Inhibitors; Proteasome Endopeptidase Complex; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Ubiquitinated Proteins; Vincristine

2021